Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its major effect is to reduce the activity ...
The global dermal regeneration market was valued at $1.1 billion in 2023, and is projected to reach $2.9 billion by 2033, growing at a CAGR of 10.2% from 2024 to 2033.